Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart Failure
BackgroundSeveral clinical studies have evaluated the association between galectin‐3 levels and outcome in patients with heart failure (HF). However, little is known about the predictive value of repeated galectin‐3 measurements. This study evaluates the prognostic value of repeated time‐dependent g...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-12-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.116.003700 |
| _version_ | 1811332283364278272 |
|---|---|
| author | Laura C. van Vark Ivonne Lesman‐Leegte Sara J. Baart Douwe Postmus Yigal M. Pinto Rudolf A. de Boer Folkert W. Asselbergs Elly M. C. J. Wajon Joke G. Orsel Eric Boersma Hans L. Hillege K. Martijn Akkerhuis |
| author_facet | Laura C. van Vark Ivonne Lesman‐Leegte Sara J. Baart Douwe Postmus Yigal M. Pinto Rudolf A. de Boer Folkert W. Asselbergs Elly M. C. J. Wajon Joke G. Orsel Eric Boersma Hans L. Hillege K. Martijn Akkerhuis |
| author_sort | Laura C. van Vark |
| collection | DOAJ |
| description | BackgroundSeveral clinical studies have evaluated the association between galectin‐3 levels and outcome in patients with heart failure (HF). However, little is known about the predictive value of repeated galectin‐3 measurements. This study evaluates the prognostic value of repeated time‐dependent galectin‐3 measurements in acute HF patients. Methods and ResultsIn the TRIUMPH (Translational Initiative on Unique and Novel Strategies for Management of Patients with Heart Failure) clinical cohort study, 496 acute HF patients were enrolled in 14 hospitals in The Netherlands, between 2009 and 2014. Repeated blood samples (7) were drawn during 1‐year follow‐up. Associations between repeated biomarker measurements and the primary end point were assessed using a joint model. Median age was 74 years and 37% were women. The primary end point, composite of all‐cause mortality and HF rehospitalization, was reached in 188 patients (40%), during a median follow‐up of 325 days (interquartile range 85–401). The median baseline galectin‐3 level was 24 ng/mL (interquartile range 18–34). The mean number of galectin‐3 measurements available per patient was 4.3. After adjustment for clinical factors and N‐terminal pro‐brain natriuretic peptide, there was a weak association between baseline galectin‐3 and risk of the primary end point. When repeated measurements were taken into account, the adjusted hazard ratio per 1 SD increase of the galectin‐3 level (on the log2 scale) at any time point increased to 1.67 (95% confidence interval, 1.24–2.23, P<0.001). After additional adjustment for repeated N‐terminal pro‐brain natriuretic peptide measurements, the association remained statistically significant. ConclusionsRepeated galectin‐3 measurements appeared to be a strong predictor of outcome in acute HF patients, independent of N‐terminal pro‐brain natriuretic peptide. Hence, galectin‐3 may be helpful in clinical practice for prognostication and treatment monitoring. |
| first_indexed | 2024-04-13T16:34:28Z |
| format | Article |
| id | doaj.art-ba155db4419a4fef815a9a33858728ec |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-04-13T16:34:28Z |
| publishDate | 2017-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-ba155db4419a4fef815a9a33858728ec2022-12-22T02:39:29ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802017-12-0161210.1161/JAHA.116.003700Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart FailureLaura C. van Vark0Ivonne Lesman‐Leegte1Sara J. Baart2Douwe Postmus3Yigal M. Pinto4Rudolf A. de Boer5Folkert W. Asselbergs6Elly M. C. J. Wajon7Joke G. Orsel8Eric Boersma9Hans L. Hillege10K. Martijn Akkerhuis11Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The NetherlandsDepartment of Epidemiology, University Medical Center Groningen University of Groningen, The NetherlandsDepartment of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The NetherlandsDepartment of Epidemiology, University Medical Center Groningen University of Groningen, The NetherlandsDepartment of Cardiology, Academic Medical Center, Amsterdam, The NetherlandDepartment of Cardiology, University Medical Center Groningen University of Groningen, The NetherlandsDepartment of Cardiology, Division Heart & Lungs, UMC Utrecht, Utrecht, The NetherlandsDepartment of Cardiology, Medical Spectrum Twente, Enschede, The NetherlandsDepartment of Precision and Decentralized Diagnostics, Philips Research, Eindhoven, The NetherlandsDepartment of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The NetherlandsDepartment of Epidemiology, University Medical Center Groningen University of Groningen, The NetherlandsDepartment of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The NetherlandsBackgroundSeveral clinical studies have evaluated the association between galectin‐3 levels and outcome in patients with heart failure (HF). However, little is known about the predictive value of repeated galectin‐3 measurements. This study evaluates the prognostic value of repeated time‐dependent galectin‐3 measurements in acute HF patients. Methods and ResultsIn the TRIUMPH (Translational Initiative on Unique and Novel Strategies for Management of Patients with Heart Failure) clinical cohort study, 496 acute HF patients were enrolled in 14 hospitals in The Netherlands, between 2009 and 2014. Repeated blood samples (7) were drawn during 1‐year follow‐up. Associations between repeated biomarker measurements and the primary end point were assessed using a joint model. Median age was 74 years and 37% were women. The primary end point, composite of all‐cause mortality and HF rehospitalization, was reached in 188 patients (40%), during a median follow‐up of 325 days (interquartile range 85–401). The median baseline galectin‐3 level was 24 ng/mL (interquartile range 18–34). The mean number of galectin‐3 measurements available per patient was 4.3. After adjustment for clinical factors and N‐terminal pro‐brain natriuretic peptide, there was a weak association between baseline galectin‐3 and risk of the primary end point. When repeated measurements were taken into account, the adjusted hazard ratio per 1 SD increase of the galectin‐3 level (on the log2 scale) at any time point increased to 1.67 (95% confidence interval, 1.24–2.23, P<0.001). After additional adjustment for repeated N‐terminal pro‐brain natriuretic peptide measurements, the association remained statistically significant. ConclusionsRepeated galectin‐3 measurements appeared to be a strong predictor of outcome in acute HF patients, independent of N‐terminal pro‐brain natriuretic peptide. Hence, galectin‐3 may be helpful in clinical practice for prognostication and treatment monitoring.https://www.ahajournals.org/doi/10.1161/JAHA.116.003700biomarkergalectin‐3heart failurerepeated measurements |
| spellingShingle | Laura C. van Vark Ivonne Lesman‐Leegte Sara J. Baart Douwe Postmus Yigal M. Pinto Rudolf A. de Boer Folkert W. Asselbergs Elly M. C. J. Wajon Joke G. Orsel Eric Boersma Hans L. Hillege K. Martijn Akkerhuis Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart Failure Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease biomarker galectin‐3 heart failure repeated measurements |
| title | Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart Failure |
| title_full | Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart Failure |
| title_fullStr | Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart Failure |
| title_full_unstemmed | Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart Failure |
| title_short | Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart Failure |
| title_sort | prognostic value of serial galectin 3 measurements in patients with acute heart failure |
| topic | biomarker galectin‐3 heart failure repeated measurements |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.116.003700 |
| work_keys_str_mv | AT lauracvanvark prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT ivonnelesmanleegte prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT sarajbaart prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT douwepostmus prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT yigalmpinto prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT rudolfadeboer prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT folkertwasselbergs prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT ellymcjwajon prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT jokegorsel prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT ericboersma prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT hanslhillege prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure AT kmartijnakkerhuis prognosticvalueofserialgalectin3measurementsinpatientswithacuteheartfailure |